Navigation Links
CASiGEN Pharma Receives A World-wide Exclusive License From GIBH To Bring New Potential Diabetes Treatments To The Global Market
Date:5/17/2012

BOSTON and HONG KONG, May 17, 2012 /PRNewswire/ -- Ventac Partners and the Guangzhou Institute of Biomedicine and Health, Chinese Academy of Sciences (GIBH) today announced the creation of CASiGEN Pharma Ltd. (CASiGEN) to bring new treatments for diabetes and other metabolic disorders to the global market. CASiGEN received a world-wide exclusive license from GIBH that gives it access to new drug candidates addressing unmet medical needs in this field. CASiGEN is currently seeking investors to advance development of selected orally available small molecules targeting the ERR-alpha receptor as a potential diabetes treatment. The Company will apply to join the Hong Kong Science & Technology Parks (HKSTP), a world class research park based in Hong Kong and within the Guangzhou region.

(Logo: http://photos.prnewswire.com/prnh/20120517/NE09478LOGO )

Commenting about the license agreement, Dr. Duanqing Pei, Director General at GIBH, said: "The license agreement with CASiGEN Pharma constitutes an important milestone for GIBH as it takes a key research project to the global market in collaboration with an international team of pharma and biotech people from the United States and Europe. We are grateful to HKSTP for initiating  a survey of the entire Pearl River Delta Region in 2008/09. It is through this initiative that we now see CASiGEN Pharma becoming a reality."

Mr. Anthony Tan, CEO of Hong Kong Science & Technology Parks Corporation (HKSTPC), said that: "We are pleased to have catalyzed the collaboration between an esteemed Chinese Academy of Science Institute and Ventac Partners, resulting in a spinoff company in Hong Kong. HKSTPC provides facilities, services and a dynamic environment that enable companies to nurture ideas, innovate and develop. We look forward to receiving an application from CASiGEN Pharma. CASiGEN Pharma could potentially be an excellent
'/>"/>

SOURCE Ventac Partners
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Thomson Scientific Publishes The Ones to Watch - A Quarterly Review of Phase Changes in the Pharmaceutical Pipeline
2. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
3. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
4. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
5. Clinical Trial Effectiveness: How Pharmas & Biotechs Save Cost with Savvy Investigator Management
6. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
7. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
8. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
9. Par Pharmaceutical Begins Shipment of Additional Dosage Strength of Generic TOPROL-XL(R)
10. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
11. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... CHARLOTTESVILLE, Va. and AUSTIN, ... PhosImmune Inc. and PureMHC LLC today announced they ... to develop novel antibody-based immunotherapies designed to target ... identification of phosphorylated peptides displayed on the surfaces ... These phosphopeptide tumor targets (PTTs), derived from proteins ...
(Date:10/22/2014)... 22, 2014  AcelRx Pharmaceuticals, Inc. (NASDAQ: ... the  IAP310 study have been published in ... peer-reviewed journal with broad, multidisciplinary readership. IAP310 was ... safety and efficacy of Zalviso, also referred to ... the treatment of post-operative pain in patients following ...
(Date:10/22/2014)... , Oct. 22, 2014  Regulus Therapeutics ... biopharmaceutical company leading the discovery and development ... that it has demonstrated human proof-of-concept with ... study evaluating RG-101, a wholly-owned, GalNac-conjugated anti-miR ... hepatitis C virus infection ("HCV").  Interim results ...
Breaking Medicine Technology:Biotech Companies To Co-Discover And Co-Develop Antibodies Targeting Novel Phosphopeptide Tumor Targets 2AcelRx Announces Publication of Zalviso Phase 3 Abdominal Trial Results 2A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 2A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 3A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 4A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 5A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 6A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 7A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 8
... 2011 /PRNewswire/ -- PRA, a leading Clinical ... Romania to further strengthen our coverage of the Balkan ... projects in the neighboring Republic of Moldova. ... in Romania, the PRA staff has steadily increased and ...
... Aug. 22, 2011 Reportlinker.com announces ... is available in its catalogue: ... Assessments of Leading Suppliers ... This report provides diagnostic imaging industry ...
Cached Medicine Technology:PRA Opens Office in Romania 2Global MRI Market: Strategic Assessments of Leading Suppliers 2Global MRI Market: Strategic Assessments of Leading Suppliers 3Global MRI Market: Strategic Assessments of Leading Suppliers 4Global MRI Market: Strategic Assessments of Leading Suppliers 5
(Date:10/20/2014)... PA (PRWEB) October 20, 2014 Allegheny ... minimally-invasive procedure that enables physicians to repair a damaged ... The MitraClip system, developed by Abbott ... (MR), a progressive and life-threatening condition in which the ... blood to flow backward from the heart’s left ventricle ...
(Date:10/20/2014)... 2014 ASCNYC (ascnyc.org) is a ... New Yorkers living with HIV/AIDS and other chronic ... recovery and self-sufficiency. Each year, ASCNYC spotlights selected ... through their tireless efforts. , Savills Studley ... has been selected as this year’s honoree for ...
(Date:10/20/2014)... T.E.N., a technology and information security ... William H. Murray, renowned author and industry visionary, ... Award winner. Presented annually, the ISE® Luminary Leadership ... and industry practitioner for his or her distinguished ... security industry. , Formerly with IBM, Murray is ...
(Date:10/20/2014)... Zereana Jess-Huff, a 34-year-old mother, corporate executive and ovarian ... to think outside the bra. She doesn’t try to hide ... awareness about women’s other lady parts. , "We have won ... color pink and everybody knows what you’re talking about,” Jess-Huff ... has not been won when it comes to gynecologic cancers. ...
(Date:10/20/2014)... 2014 My Clients Plus ( http://www.MyClientsPlus.com ... The new module enables easy administration and routing ... quality care. , This application allows users such as ... attach a to-do item to a specific client, categorize ... up reoccurring reminders for follow-ups. It's designed to ...
Breaking Medicine News(10 mins):Health News:Allegheny General Hospital Introduces New, Beating-Heart Procedure for Mitral Valve Repair 2Health News:Allegheny General Hospital Introduces New, Beating-Heart Procedure for Mitral Valve Repair 3Health News:Savills Studley's Marc Shapses To Be Honored as 2014 "Positive Changemaker" by ASCNYC 2Health News:Savills Studley's Marc Shapses To Be Honored as 2014 "Positive Changemaker" by ASCNYC 3Health News:Bill Murray named 2014 ISE® Luminary Leadership Award Winner 2Health News:Bill Murray named 2014 ISE® Luminary Leadership Award Winner 3Health News:Bill Murray named 2014 ISE® Luminary Leadership Award Winner 4Health News:Ovarian Cancer Survivor Mrs. Maryland Urges Media to Think Outside the Bra 2Health News:Ovarian Cancer Survivor Mrs. Maryland Urges Media to Think Outside the Bra 3Health News:My Clients Plus Announces New Workflow Management Software 2
... technology to process the conversion of medical records from microfiche to ... ... 2009 -- Penny Imaging Exchange, Inc. (PIE) has acquired new technology ... form - the DRS Digitizer . With the Obama administration ...
... CHICAGO, April 17 Specialty Underwriters, Alliance, Inc. ... announced today that Glass Lewis & Co., a leading ... WHITE proxy card and do not vote for the nominees ... SUA,s Annual Meeting of Stockholders will be held at 9:00 ...
... Volunteer Week, is April 19 - April 25 ... today praised Pennsylvania,s volunteers for selflessly giving their time ... and urged other citizens to join those important efforts. ... opportunity to thank our volunteers for generously sharing their ...
... Assurance solutions help MEDNAX increase security and simplify ... Corporation , leaders in access governance, provisioning ... implemented the company,s Enterprise Suite to assure access ... 5,000 clinical and administrative employees. MEDNAX is ...
... such study involves effort to improve chemotherapy effectiveness , , FRIDAY, ... research and testing, only a small percentage of cancer agents ... have come up with a way to weed out the ... the marketplace. , The new model, a so-called "phase ...
... South Florida physician Sanford Siegal, D.O., M.D., explains why ... and reveals how to overcome this obstacle to reaching ... Sanford Siegal, Medical Director of Miami, Florida-based weight-loss practice, ... among dieters that the most challenging part of reaching ...
Cached Medicine News:Health News:Penny Imaging Exchange, Inc. Acquires New Technology to Capture Medical Records from Microfiche 2Health News:Penny Imaging Exchange, Inc. Acquires New Technology to Capture Medical Records from Microfiche 3Health News:Leading Independent Proxy Advisory Firm Supports Specialty Underwriters' Alliance, Inc. in Its Proxy Contest Against Hallmark Financial Services, Inc. 2Health News:Leading Independent Proxy Advisory Firm Supports Specialty Underwriters' Alliance, Inc. in Its Proxy Contest Against Hallmark Financial Services, Inc. 3Health News:PA Secretary of Health Recognizes Pennsylvania Volunteers; Urges Greater Citizen Involvement 2Health News:MEDNAX National Medical Group(TM) Uses Courion's Enterprise Suite to Automate Identity and Access Management 2Health News:MEDNAX National Medical Group(TM) Uses Courion's Enterprise Suite to Automate Identity and Access Management 3Health News:'Phase 0' Trials Aim to Speed Cancer Drug Development 2Health News:'Phase 0' Trials Aim to Speed Cancer Drug Development 3Health News:Losing the Last Ten Pounds is the Hardest Part of any Diet Confirms Weight-Loss Expert and Author Dr. Sanford Siegal 2
Research Series 2100 Adjustable-volume Pipette,100-1,000 l, single-channel with adjustable-volume setting...
... operations, the Sysmex KX-21N is ideal ... lab testing. This 3-part differential ... Built on the reliable, field proven ... a completely automatic START-UP function and ...
... of pacemakers features several of the ... in today's worldwide pacing market. Offering ... and diagnostic information, the system builds ... pacemakers platform. , ,It incorporates ...
... of pacemakers features several of the ... in today's worldwide pacing market. Offering ... and diagnostic information, the system builds ... pacemakers platform. , ,It incorporates ...
Medicine Products: